Você procurou por: inferioritet (Dinamarquês - Inglês)

p-værdi (non-inferioritet)
p value (noninferiority)

p-værdi for non-inferioritet (hr)
non-inferiority p-value (hr)

der blev ikke opnået statistisk non- inferioritet.
statistical non-inferiority was not achieved.

konklusionerne understøttede non-inferioritet uanset analysemetode.
conclusions supported non-inferiority regardless of analysis method.

rosiglitazon viste ikke non-inferioritet over for metformin.
rosiglitazone failed to demonstrate non-inferiority to metformin.

immunologisk non-inferioritet over for 7-valent prevenar
immunologic non-inferiority to 7-valent prevenar

non-inferioritet i forhold til sevelamercarbonat blev bestemt ved uge 12.
non-inferiority to sevelamer carbonate was determined at week 12.

ap<0,0001 for vurdering af non-inferioritet i forhold til p.n.
ap<0.0001 for assessment of non-inferiority to prn

begge analyser var dog sammenlignelige med en konklusion om ikke-inferioritet mellem begge behandlingsarme.
however, both analyses were compatible with a conclusion of non-inferiority between both treatment arms.

pregabalin opnåede ikke non-inferioritet over for lamotrigin baseret på 6 måneders anfaldsfrihed som endepunkt.
pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom endpoint.

studiet var designet til at vise sancuso’s non-inferioritet i forhold til oral granisetron.
the study was designed to show non-inferiority of sancuso to oral granisetron.

0,89 (0,70; 1,13) p-værdi < 0,0001 (non-inferioritet)
0.89 (0.70, 1.13) p-value < 0.0001 (non-inferiority)

4-ugers, non-inferioritet, blindet overkrydsningsstudie med aktiv kontrol (studie 1)
active-controlled, 4-week, noninferiority, blinded crossover study (study 1)

dette ligger godt inden for det prædefinerede kriterium for non- inferioritet med 4 point i middelforskellen mellem grupperne, justeret for basislinie for twstrs.
the upper limit of the 1-sided ci in the ls mean difference (neurobloc - type a toxin) in the twstrs total score at week 4 of session 1 for the pp population (excluding site 121) was 0.6 which is well within the predefined criterion for noninferiority of 4 points in the mean difference between groups adjusted for baseline for the twstrs.

effektanalyser med brug af pq-populationen er konsistente med analyser for itt-populationen og understøtter non- inferioritet af ac mod gc.
the efficacy analyses using pq population are consistent with the analyses for the itt population and support the non-inferiority of ac versus gc.

formålet med studiet var at vise non-inferioritet af spectrila i forhold til referencen e. coli-asparaginase med hensyn til det primære endepunkt.
the objective of the study was to demonstrate the non-inferiority of spectrila to the reference e. coli-asparaginase with regard to the primary endpoint.

der blev hverken vist forbedring eller non- inferioritet til ob alene i dette forsøg, skønt der ikke var negativt resultat af viralbelastning eller cd4+- celletal.
in this study, neither superiority nor non-inferiority to obt alone were demonstrated although there was no adverse outcome on viral load or cd4+ cell count

på grund af valsartans non- inferioritet i kliniske resultater sammenlignet med den aktuelle standardbehandling, en ace- hæmmer, vedtog chmp følgende harmoniserede formulering for denne indikation:
considering the non inferiority in clinical outcome of valsartan compared to current standard treatment, an acei, the chmp adopted the following harmonised wording for this indication:

den nedre grænse for konfidensintervallet på 95 % lå over den prædefinerede non-inferioritetsmargin på -10 %, og viste derfor non-inferioritet.
the lower limit of the 95% ci was above the predefined non-inferiority margin of -10%, proving non-inferiority.

det første sekundære endpoint i forsøget viste også sammenlignelig effekt (non- inferioritet) mellem 100 mg dagligt og 140 mg dagligt (forskel i mcyr - 0, 8%; 95% konfidensinterval [- 9, 6% - 8, 0%]).
the main secondary endpoint of the study also showed comparable efficacy (non-inferiority) between the 100 mg total daily dose and the 140 mg total daily dose (difference in mcyr -0.8%; 95% confidence interval [-9.6% - 8.0%]).